**Supplemental TABLE 4.** Serious adverse events and adverse events leading to discontinuation the from treatment period, study 1031 (N=268)

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Serious AE** | **AE leading to Discontinuation**\* | **Event details†** |
| Patients with any event, n (%) | 10 (3.7) | 14 (5.2) |  |
| Aggression  Irritability  Frustration  Hallucination (auditory)  Elevated mood  Insomnia | 1 | 1 | 13 yo female, 25 mg/d; serious AEs aggression toward self and others, frustration, and irritability resulted in discontinuation at study day 19 and received her last dose of desvenlafaxine on this day. The patient remained in the acute psychiatric inpatient unit from day 19 to day 29 and then required partial hospitalization in a day treatment program starting on day 30 to be monitored for safety and to start additional medication. The patient recovered from the events of Aggression, Frustration and Irritability on day 33.  On day 39, the patient experienced auditory hallucinations, elevated mood, and insomnia; these events prolonged the patient’s psychiatric day treatment. The event hallucination (auditory) remained ongoing at the last study visit. The patient completed the day treatment program and recovered from the events elevated mood and Insomnia on day 52. |
| Appendicitis | 1 |  | 11 yo male, 35 mg/d; continued in study after emergency appendectomy on study day 50 |
| Asthma | 1 |  | 10 yo male, 25 mg/d; study medication interrupted after hospitalization for asthma on study day 178, patient recovered and restarted desvenlafaxine at day 180 |
| Hallucination (auditory)  Self-injurious behavior | 1 | 1 | 9 yo female, 35 mg/d; patient reported that she had cut herself with a butter knife, a tack, and a twist tie; she was hospitalized for self-injurious behavior and auditory hallucination on study day 26. Relevant tests included a urine drug screen on day 26, which was positive for cannabinoids, and a quantitative drug screen on day 27 was 17 ng/mL (reference range 0 to 5 ng/mL). The hallucination was considered likely due to cannabinoid use. Desvenlafaxine was discontinued on day 29 in response to the event of Self injurious behavior. On day 33, the patient returned for the Early Termination visit with no presentation of hallucinations or suicidal ideation. The patient was discontinued from the study on day 61 |
| Ovarian cyst | 1 |  | 12 yo female, 50 mg/d; patient went to the ER on study day 152 with abdominal pain, and a large ovarian cyst and the ovary were removed in an emergency surgery on study day 154. The patient was discharged from the hospital on day 155 and continued in the study |
| Suicide attempt  Overdose | 1 | 1 | 12 yo male, 25 mg/d; patient was discontinued and hospitalized on study day 36 in response to 2 suicide attempts (overdose and cutting) on days 34 and 35. The patient was considered to have recovered from the events on day 35 and was discharged from the hospital on day 41. |
| Suicide attempt | 4 | 4 | 16 yo male, 35 mg/d; patient thought about cutting himself and planned a suicide note on study day 31. The event was not reported until study day 41. The patient was discontinued from the treatment phase in response to this event on day 41. The patient recovered from the event on the date of onset (day 31).  11 yo female, 50 mg/d; the patient was hospitalized after an attempted overdose on study day 182. Desvenlafaxine was discontinued in response to this event; the last dose was administered on day 181. The patient was discontinued from the study on day 189. The patient recovered from the event on day 192 and was discharged from the hospital on that date.  10 yo female, 35 mg/d; the patient was discontinued (not hospitalized) on study day 9 after she climbed to her roof and threatened to jump. The serious adverse event was considered to be resolved on the same day.  15 yo female, 25 mg/d; patient was discontinued from study on day 18 after planning to cut herself with a razor. She was hospitalized for the event on day 19, recovered from the event on day 25, and was discharged from the psychiatric hospital on this day. She was hospitalized again after an attempted overdose at study day 43 (post-therapy). The patient recovered from the event on day 52 and was discharged from the psychiatric hospital on this day. |
| Aggression |  | 1 | 7 yo male, 25 mg/d; treatment was discontinued on study day 85 after an event of aggression on study day 77 |
| Dyspepsia |  | 1 | 10 yo female, 25 mg/d; discontinued on study day 39 due to dyspepsia after a temporary dose decrease due to nausea and vomiting |
| Galactorrhea |  | 1 | 17 yo female, 50 mg/d; discontinued on study day 61 |
| Hallucination (auditory) |  | 1 | 9 yo female, 25 mg/d; discontinued on study day 10; last dose was day 6 |
| Irritability |  | 1 | 7 yo male, 25 mg/d; discontinued study day 64 |
| Suicidal ideation |  | 1 | 15 yo female, 50 mg/d; discontinued study day 53; last dose was day 51 |
| Vomiting |  | 1 | 14 yo female, 25 mg/d; discontinued study day 6; last dose was day 5 |

ER, emergency room; yo, year old.

\*Sites were instructed that if the reason for withdrawal included two or more adverse events, the most serious adverse event was considered the primary reason for withdrawal.

†The dose listed is desvenlafaxine dose at the time of the event, or the last desvenlafaxine dose taken prior to the event for events that occurred post-therapy; day of last dose is reported where it differed from day of discontinuation.